drugset / Trial / NCT02500485

The Drug-drug Interaction of SHR3824 and SP2086

NCT02500485

Phase 1 Unknown 12 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and multiple oral doses of SP2086 in healthy adult volunteers.

Timeline

Start
2015-05
Primary completion
2015-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Henagliflozin Small molecule 20 mg Oral
Subject Retagliptin Small molecule 100 mg Oral